OncoMatch/Clinical Trials/NCT06666270
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Is NCT06666270 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SYN818 for advanced solid cancer.
Treatment: SYN818 — This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Ovarian Cancer
Breast Carcinoma
Prostate Cancer
Biomarker criteria
Required: BRCA1 mutation
Required: BRCA2 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care
disease progression, and available SOC therapies had been exhausted
Cannot have received: POLQ inhibitor
Previous or current use of POLQ inhibitors
Lab requirements
Blood counts
No serious hematological diseases other than the primary disease; adequate bone marrow function
Kidney function
No serious kidney diseases other than the primary disease; adequate organ function
Liver function
No serious liver diseases other than the primary disease; adequate organ function
Cardiac function
No serious cardiopulmonary diseases other than the primary disease
No serious hematological, cardiopulmonary, or liver or kidney diseases other than the primary disease; Adequate organ function and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify